Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Insiders at Synageva BioPharma and Bind Therapeutics Buy Shares

By

Plus, there were purchases at Accuride and Weatherford International.

PrintPRINT
Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Friday, September 27, 2013.

Notables Purchases:
  • Julian Baker, a director at clinical stage biopharmaceutical company Synageva BioPharma (NASDAQ:GEVA), bought 1,050,000 shares of company stock for $59,461,500.
  • The privately owned hedge fund sponsor Coliseum Capital Management bought 414,481 shares of the manufacturer and supplier of commercial vehicle components Accuride (NYSE:ACW) for $2,139,591.
  • Rusnano, the joint-stock company created and owned by the Russian government that seeks to commercialize developments in nanotechnology, bought 120,000 shares of clinical-stage nanomedicine platform company Bind Therapeutics (NASDAQ:BIND) for $1,800,000.
  • William Macaulay, a director at Weatherford International (NYSE:WFT), bought 78,000 shares of company stock for $1,189,890.
For more insider trading, see the charts belows.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
DIR,BO
JB*
$59,461,500
2
BO
B
$2,139,591
3
BO
JB*
$1,800,000
4
DIR
B
$1,189,890
5
DIR,BO
B
$523,983
6
PR,CEO,DIR
JB*
$405,000
7
BO
JB*
$390,000
8
BO
JB*
$300,000
9
GC
JB*
$270,000
10
COO
JB*
$270,000

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
CB,DIR
AS
$89,547,998
2
DIR,BO
JS*
$66,899,384
3
DIR,BO
JS*
$38,203,140
4
CB,DIR
S
$16,139,879
5
PR,CEO,DIR
AS
$5,117,928
6
BO
S
$5,102,359
7
DIR
S
$2,700,342
8
BO
S
$2,411,359
9
DIR
AS
$1,571,000
10
VP,COO
S
$1,550,478

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
PrintPRINT

Busy? Subscribe to our free newsletter!

Submit
 

WHAT'S POPULAR IN THE VILLE